118 related articles for article (PubMed ID: 7113961)
1. Phase II trial of bruceantin in metastatic breast carcinoma.
Wiseman CL; Yap HY; Bedikian AY; Bodey GP; Blumenschein GR
Am J Clin Oncol; 1982 Aug; 5(4):389-91. PubMed ID: 7113961
[TBL] [Abstract][Full Text] [Related]
2. A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma.
Arseneau JC; Wolter JM; Kuperminc M; Ruckdeschel JC
Invest New Drugs; 1983; 1(3):239-42. PubMed ID: 6678872
[TBL] [Abstract][Full Text] [Related]
3. Phase I study on bruceantin administered on a weekly schedule.
Liesmann J; Belt RJ; Haas CD; Hoogstraten B
Cancer Treat Rep; 1981; 65(9-10):883-5. PubMed ID: 7273023
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma.
Amato DA; Borden EC; Shiraki M; Enterline HT; Rosenbaum C; Davis HL; Paul AR; Stevens CM; Lerner HJ
Invest New Drugs; 1985; 3(4):397-401. PubMed ID: 2417985
[TBL] [Abstract][Full Text] [Related]
5. Initial clinical studies with bruceantin.
Bedikian AY; Valdivieso M; Bodey GP; Murphy WK; Freireich EJ
Cancer Treat Rep; 1979; 63(11-12):1843-7. PubMed ID: 526918
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of bruceantin by radioimmunoassay.
Fong KL; Ho DH; Benjamin RS; Brown NS; Bedikian A; Yap BS; Wiseman CL; Kramer W; Bodey GP
Cancer Chemother Pharmacol; 1982; 9(3):169-72. PubMed ID: 7160053
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of bruceantin.
Garnick MB; Blum RH; Canellos GP; Mayer RJ; Parker L; Skarin AT; Li FP; Henderson IC; Frei E
Cancer Treat Rep; 1979; 63(11-12):1929-32. PubMed ID: 526926
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunoassay for the detection and quantitation of bruceantin.
Fong KL; Ho DH; Carter CJ; Brown NS; Benjamin RS; Freireich EJ; Bodey GP
Anal Biochem; 1980 Jul; 105(2):281-6. PubMed ID: 7457834
[No Abstract] [Full Text] [Related]
9. Antitumor activity of novel ailanthone derivatives in vitro and in vivo.
Kato T; Suzumura Y; Fukushima M; Honda T; Nakanishi T; Noguchi T
Anticancer Res; 1988; 8(4):573-9. PubMed ID: 3178149
[TBL] [Abstract][Full Text] [Related]
10. Yadanzioside P, a new antileukemic quassinoid glycoside from Brucea javanica (L.) Merr with the 3-O-(beta-D-glucopyranosyl)bruceantin structure.
Sakaki T; Yoshimura S; Tsuyuki T; Takahashi T; Honda T
Chem Pharm Bull (Tokyo); 1986 Oct; 34(10):4447-50. PubMed ID: 3829175
[No Abstract] [Full Text] [Related]
11. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
Rivera E; Holmes FA; Frye D; Valero V; Theriault RL; Booser D; Walters R; Buzdar AU; Dhingra K; Fraschini G; Hortobagyi GN
Cancer; 2000 Dec; 89(11):2195-201. PubMed ID: 11147589
[TBL] [Abstract][Full Text] [Related]
12. Antimalarial activity of bruceantin in vitro.
Guru PY; Warhurst DC; Harris A; Phillipson JD
Ann Trop Med Parasitol; 1983 Aug; 77(4):433-5. PubMed ID: 6357122
[No Abstract] [Full Text] [Related]
13. Phase II study of anguidine in advanced breast cancer.
Yap HY; Murphy WK; DiStefano A; Blumenschein GR; Bodey GP
Cancer Treat Rep; 1979 May; 63(5):789-91. PubMed ID: 455316
[TBL] [Abstract][Full Text] [Related]
14. Antitumor agents XLII: Comparison of antileukemic activity of helenalin, brusatol, and bruceantin and their esters on different strains of P-388 lymphocytic leukemic cells.
Hall IH; Lee KH; Okano M; Sims D; Ibuka T; Liou YF; Imakura Y
J Pharm Sci; 1981 Oct; 70(10):1147-50. PubMed ID: 7299649
[TBL] [Abstract][Full Text] [Related]
15. Quassinoid bitter principles. II.
Polonsky J
Fortschr Chem Org Naturst; 1985; 47():221-64. PubMed ID: 3896993
[No Abstract] [Full Text] [Related]
16. 1H- and 13C-NMR spectroscopic studies of selected quassinoids.
Hamburger MO; Cordell GA
Planta Med; 1988 Aug; 54(4):352-5. PubMed ID: 3222379
[No Abstract] [Full Text] [Related]
17. Bruceantin, a potent amoebicide from a plant, Brucea antidysenterica.
Gillin FD; Reiner DS; Suffness M
Antimicrob Agents Chemother; 1982 Aug; 22(2):342-5. PubMed ID: 6100431
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
[TBL] [Abstract][Full Text] [Related]
19. Reversibility of protein synthesis inhibition by quassinoid antineoplastic agents in a rabbit reticulocyte system.
Willingham W; Considine RT; Chaney SG; Lee KH; Hall IH
Biochem Pharmacol; 1984 Jan; 33(2):330-3. PubMed ID: 6704156
[No Abstract] [Full Text] [Related]
20. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience.
Bruno S; Puerto VL; Mickiewicz E; Hegg R; Texeira LC; Gaitan L; Martinez L; Fernandez O; Otero J; Kesselring G
Am J Clin Oncol; 1995 Oct; 18(5):392-6. PubMed ID: 7572754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
